Real-world data is an important supplement to evidence gained from clinical trials regarding the use of disease-modifying therapies in multiple sclerosis. In this touchNEUROLOGY interview, Dr Melinda Magyari (University of Copenhagen, Copenhagen, Denmark) shares her thoughts on the benefits of real-world data, how ‘big data’ can help physicians understand treatment characteristics, and the future impact of incorporating this data into management of multiple sclerosis.
1. Randomized controlled trials are the gold standard for supporting the approval of interventions; what benefits are gained when exploring real-world data for the impact of treatments? (00:15)
2. How can ‘big data’ help physicians understand treatment characteristics in the population of people with multiple sclerosis, and what do you think the most important signals are? (00:56)
3. What evidence exists to support physicians in deciding when to initiate, switch or cease a pharmaceutical intervention? (01:34)
4. What do you see as the future impact of incorporating more real-world data into the understanding of management of multiple sclerosis? (02:26)
The abstract titled ‘Real-World-Evidence (Big data, registries): “game-changer” for regulatory and clinical views on when to start, switch and stop of disease-modifying therapies in MS?’ (Abstract #SYMP02-4) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosures: Melinda Magyari has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
Click here for more content on this topic.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!